148 DIAGEO ANNUAL REPORT 2017 Financial statements of the company: Notes to the company financial statements of Diageo plc 3.
Investment in subsidiary undertakings Financial instruments Derivative financial instruments are recognised in the balance sheet million at fair value calculated using discounted cash flow techniques based Cost less provisions on market data applied consistently for similar types of instruments.
At 30 June 2016 27,038 Changes in the fair value of derivatives are reported in the statement Additions a 3 of income.
Gains and losses on derivatives that do not qualify for At 30 June 2017 27,041 hedge accounting treatment are taken to the statement of income as they arise.
Significant assumptions underlying the valuation models and Investments in subsidiaries are stated at historical cost of 27,327 techniques used are disclosed in note 15 to the consolidated financial million 2016 27,324 million less impairment provisions of 286 statements.
Amounts owed by and to other group companies are initially a Investment in subsidiaries include 127 million 2016 124 million measured at fair value and are subsequently reported at amortised of costs in respect of share-based payments, granted to subsidiary cost.
Non-interest bearing receivables and payables are stated at their undertakings which were not recharged to the subsidiaries.
In the nominal value as they are due on demand.
year ended 30 June 2017 the company recognised additions of For a number of loans owed to other group companies, the 3 million 2016 2 million in respect of options not recharged.
company has a contractual right to defer payment by one year and one day and therefore these amounts are disclosed as nonA list of group companies as at 30 June 2017 is provided in note 11. current liabilities.
Other financial assets and liabilities Financial guarantee contract liabilities At 30 June 2017 financial assets and liabilities comprise the fair value Financial guarantee contract liabilities are measured initially at their of interest rate swaps and cross currency interest rate swaps with fair values.
These liabilities are subsequently measured at the higher subsidiary undertakings, where the company acts as an intermediary of the amount determined under IAS 37 and the amount initially between group companies, therefore it is not expected that there recognised fair value less where appropriate, cumulative will be any net impact on future cash flows.
amortisation of the initial amount recognised.
Information on financial risk management for the group is presented in note 15 to the consolidated financial statements.
Critical accounting estimates and judgements The companys critical accounting policies, which the Directors 5.
Deferred tax assets and liabilities consider are of greater complexity and or particularly subject The amounts of deferred tax accounted for in the balance sheet to the exercise of judgements are the same as those disclosed in comprises the following net deferred tax assets liabilities : note 1 to the consolidated financial statements in respect of taxation, Post Other post-employment benefit, contingent liabilities and legal employment temporary plans differences Total proceedings.
A critical accounting estimate, specific to the company, million million million is the assessment that the recoverable amount of the companys At 30 June 2015 60 53 7 investment in subsidiaries is greater than the carrying amount.
Recognised in statement of income 1 11 12 Recognised in other comprehensive 2.
Statement of income income and equity 89 1 90 Note 3 to the consolidated financial statements provides details At 30 June 2016 28 43 71 of the remuneration of the companys auditor for the group.
Recognised in statement of income 6 6 Information on directors emoluments, share and other interests, Recognised in other comprehensive transactions and pension entitlements is included in the Directors income and equity 40 1 41 remuneration report in this Annual Report.
At 30 June 2017 18 42 24 Deferred tax on other temporary differences includes assets in respect of the UK Thalidomide Trust liability of 36 million 2016 35 million and share-based payment liabilities of 6 million 2016 7 million.
